NCT05743543

A Pilot Study of SPG Block for PTSD

A Feasibility Study of a Sphenopalatine Ganglion (SPG) Block for Post Traumatic Stress Disorder (PTSD)

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.

Detailed description

The sphenopalatine ganglion (SPG) is a collection of neurons involved in autonomic regulation (which refers to bodily processes that are automatic like heart rate and blood pressure). Blocking the SPG is used to treat disorders, such as migraines or cluster headaches (short, severe headaches that occur together). The procedure will be performed by a doctor who specializes in ear, nose throat surgery. The block consists of the injection of a numbing agent (similar to the type used by dentists) to the SPG. After the SPG block, we will follow patients for 8 weeks to see how they feel.

Conditions

• Post Traumatic Stress Disorder

Interventions

Type	Name	Description
OTHER	Sphenopalatine ganglion block	The block is performed with a nasoscope and the administration of a local anesthetic.

Timeline

• Start date: 2019-05-28
• Primary completion: 2023-06-01
• Completion: 2023-06-01
• First posted: 2023-02-24
• Last updated: 2024-02-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study